Previous Article | Next Article 
Infection and Immunity, November 1999, p. 5985-5993, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Shiga Toxins Stimulate Secretion of Interleukin-8
from Intestinal Epithelial Cells
C. M.
Thorpe,
Bryan P.
Hurley,
Lisa L.
Lincicome,
Mary
S.
Jacewicz,
Gerald T.
Keusch, and
David W. K.
Acheson*
Division of Geographic Medicine and
Infectious Diseases, New England Medical Center, Boston,
Massachusetts 02111
Received 22 March 1999/Returned for modification 28 May
1999/Accepted 27 August 1999
 |
ABSTRACT |
In the 1980s, Shiga toxin (Stx)-producing Escherichia
coli O157:H7 (STEC) was identified as a cause of hemorrhagic
colitis in the United States and was found to be associated with
hemolytic uremic syndrome (HUS), a microangiopathic hemolytic anemia
characterized by thrombocytopenia and renal failure. The precise way
that Stxs cause hemorrhagic colitis and HUS is unclear. Stxs have been
thought to cause disease by killing or irreversibly harming sensitive cells through a nonspecific blockade of mRNA translation, eventually resulting in cytotoxicity by preventing synthesis of critical molecules
needed to maintain cell integrity. Because STEC is noninvasive, we have
been exploring the host-toxin response at the level of the
gastrointestinal mucosa, where STEC infection begins. We have found
that Stx is capable of interleukin-8 (IL-8) superinduction in a human
colonic epithelial cell line. Despite a general blockade of mRNA
translation, Stx treatment results in increased IL-8 mRNA as well as
increased synthesis and secretion of IL-8 protein. Our data suggest
that an active Stx A subunit is required for this activity. Ricin,
which has the same enzymatic activity and trafficking pathway as Stx,
has similar effects. Exploration of the effects of other protein
synthesis inhibitors (cycloheximide, anisomycin) suggests a mechanism
of gene regulation that is distinct from a general translational
blockade. Use of the specific p38/RK inhibitor SB202190 showed that
blocking of this pathway results in decreased Stx-mediated IL-8
secretion. Furthermore, Stxs induced mRNA of the primary response gene
c-jun, which was subsequently partially blocked by
SB202190. These data suggest a novel model of how Stxs contribute to
disease, namely that Stxs may alter regulation of host cell processes
in sensitive cells via activation of at least one member of the
mitogen-activated protein kinase family in the p38/RK cascade and
induction of c-jun mRNA. Stx-induced increases in chemokine
synthesis from intestinal epithelial cells could be important in
augmenting the host mucosal inflammatory response to STEC infection.
 |
INTRODUCTION |
Infection with Shiga toxin
(Stx)-producing Escherichia coli (STEC) is a cause of bloody
diarrhea and hemorrhagic colitis in humans and has been
epidemiologically associated with the subsequent development of
thrombotic microangiopathy resulting in hemolytic uremic syndrome (HUS)
(19). The pathogenomonic hallmark of diarrhea-associated thrombotic microangiopathy is the presence of fibrin-platelet thrombi
in the microvasculature of involved tissues (23, 36), but
our understanding of the role of Stxs in the pathogenesis of this
syndrome is limited. Stxs have been found in the gastrointestinal tract
of humans infected with STEC (1). Because STEC is a
noninvasive pathogen, it is proposed that Stxs gain access to the
systemic vasculature from the gut lumen and subsequently cause damage
to microvascular endothelial cells in target organs such as the kidney and the central nervous system. Indeed, we have previously demonstrated that Stxs can traverse polarized intestinal epithelial cell monolayers in tissue culture and remain biologically active (2).
Intestinal STEC infection is a complex relationship between host and
bacteria. Bacterial surface and secreted proteins, as well as host
factors that mediate the inflammatory response, are involved (24,
26). Although initial epidemiologic studies suggested that STEC
did not commonly provoke a dramatic intestinal inflammatory response
(10), it has since been demonstrated that humans with STEC
infection frequently have fecal leukocytes as well as a peripheral
leukocytosis (33). In the rabbit model of STEC-associated
hemorrhagic colitis, histopathologic specimens show severe inflammatory
colitis with polymorphonuclear infiltrates (22). STEC
infection in rabbits causes intestinal epithelial cell disruption that
is prevented by pretreatment with a monoclonal antibody to the
leukocyte adhesion molecule CD18 (8), suggesting that the
host response to infection plays a major role in STEC infection in this
model and that intestinal epithelial cell damage is not simply due to
the direct cytotoxic action of Stxs.
How this intestinal pathogen initiates the host inflammatory response
is under investigation. Chemokines of the C-X-C subfamily, such as
interleukin-8 (IL-8), are known to recruit polymorphonuclear cells into
areas of infection. Furthermore, IL-8 not only acts as a neutrophil
chemokine but can also stimulate several responses in neutrophils
essential for microbial killing, such as granule content release and
the respiratory burst. By releasing granule constituents such as
proteases, toxic oxygen products, and other proinflammatory substances,
neutrophils that migrate to the gastrointestinal tract in response to
infection can subsequently damage the intestinal mucosa (11,
35).
Enteropathogenic E. coli strains, which share several
virulence factors with STEC but do not express Stxs (24),
can attach to intestinal epithelial cell monolayers, stimulate IL-8
production, and cause neutrophil transmigration which is subsequently
attenuated by use of an anti-IL-8 antibody (31). We have
found that STEC attachment to intestinal epithelial cell monolayers can
also cause neutrophil transmigration (13). In a rabbit
model, animals infected with a rabbit enteropathogenic E. coli strain engineered to produce Stx (RDEC H19B) developed more
severe disease with increased inflammatory changes and elevated mucosal
IL-1 bioactivity levels than rabbits infected with the
non-Stx-producing parent strain (5). These findings suggest
that Stx itself, either directly or indirectly, has a significant
proinflammatory role in pathogenesis.
We are currently investigating the hypothesis that direct
proinflammatory effects of Stxs on the intestinal epithelium contribute to the disruption of this important barrier by host defenses, allowing
enhanced uptake of toxins into the underlying tissues. We describe the
effects of Stx1 and Stx2 on IL-8 mRNA levels and IL-8 protein synthesis
by a human intestinal epithelial cell line. We characterize the
apparent paradox of enhanced IL-8 secretion and inhibition of protein
synthesis by Stxs. We explore the specificity of this effect by using
other protein synthesis inhibitors that inhibit translation via
different mechanisms. We also present data suggesting that Stxs may
induce IL-8 via the ribotoxic stress response, inducing
c-jun mRNA and activating at least one mitogen-activated protein kinase (MAPK) family member in the p38/RK cascade.
 |
MATERIALS AND METHODS |
Materials.
Cell culture media and additives were purchased
from Gibco BRL-Life Technologies (Grand Island, N.Y.). IL-8
enzyme-linked immunosorbent assay (ELISA) kits and tumor necrosis
factor alpha (TNF-
) were purchased from Endogen (Woburn, Mass.).
Lectin from Ricinus communis (ricin), cycloheximide, and
lipopolysaccharide from E. coli serotype O111:B4 were
purchased from Sigma (St. Louis, Mo.). Anisomycin and SB202190 were
purchased from Calbiochem (La Jolla, Calif.). [3H]leucine
was purchased from New England Nuclear (Boston, Mass.).
Cell culture, treatments, IL-8 secretion, and protein synthesis
inhibition.
Hct-8 cells, a human colonic carcinoma cell line, were
obtained from the American Type Culture Collection (ATCC) and grown at
37°C in 5% CO2 in RPMI 1640 medium with
L-glutamine, 10% fetal calf serum, 100 units of penicillin
G sodium per ml, 100 µg of streptomycin sulfate per ml, 1 mM sodium
pyruvate, and 10 mM HEPES to 95 to 100% confluency in 6-, 24-, or
96-well culture dishes. Preliminary data demonstrated that the 50%
inhibitory dose (ID50) was variable and increased with
increasing age and plating density of cells (data not shown). For this
reason and to be consistent, cells were plated at 5 × 105 to 1 × 106 cells per ml and used at
24 to 48 h for all experiments. Confluent monolayers plated and
used in this way were sensitive to Stxs with ID50s of
approximately 1 µg/ml for Stx1 and 5 to 10 µg/ml for Stx2. Six-,
24-, or 96-well plates were seeded with 2 ml, 0.5 ml, or 0.1 ml of
cells, respectively. Cells were exposed to the following agents for 18 to 24 h: TNF-
at 10 ng/ml, Stx1 and Stx2 at a range of
concentrations from 1 ng/ml to 100 µg/ml, Stx1 and Stx2 inactivated
by boiling for 4 h at a range of doses from 1 ng/ml to 1 µg/ml,
ricin at a range of doses from 1 pg/ml to 1 ng/ml, cycloheximide at a
range of doses from 10 µg/ml to 2.5 mg/ml, and anisomycin at a range
of doses from 5 ng/ml to 10 µg/ml. For experiments using the p38
kinase inhibitor SB202190, cells were preincubated for 30 min with 3 µM inhibitor (approximately 10 times the 50% inhibitory
concentration) or the inhibitor diluent dimethylsulfamethoxide (DMSO);
then, Stx1 or anisomycin was added in the presence of either the
inhibitor or DMSO for 18 h. Cell culture supernatants were
collected, and IL-8 protein concentrations were determined by ELISA.
The effects of Stx1, Stx2, ricin, cycloheximide, and anisomycin on
protein synthesis were determined by measuring [3H]leucine incorporation in Hct-8 cells, as previously
described for Vero cells (17). Briefly, following the
various cell treatments, cell supernatants were removed and cells were
washed and then incubated for 60 min in leucine-free medium to which 1 mCi of [3H]leucine per 100 ml was added. Incorporation of
label into trichloroacetic acid-precipitable material was then
measured. Boiled toxin controls were checked for biological activity
and did not inhibit [3H]leucine incorporation in Vero cells.
RNA isolation, determination of IL-8 mRNA levels by
semiquantitative RT-PCR, and Northern blotting.
Primer selections
for IL-8 and
-actin genes were based on previously published
sequences (18). Cells were treated with agents for 4 to
6 h. For experiments using the p38 kinase inhibitor SB202190,
cells were preincubated for 30 min with 3 µM inhibitor or the
inhibitor diluent DMSO; then, Stxs or anisomycin was added in the
presence of either the inhibitor or DMSO for 4 h. Total RNA was
recovered by one of the following two methods. The first method
included lysis of cell monolayers in TriReagent (Sigma), followed by
homogenization in QIAshredder spin columns (QIAGEN Inc., Santa Clarita,
Calif.). Lysates underwent chloroform extraction, isopropanol
precipitation, and washing with 70% ethanol in diethyl pyrocarbonate-treated water. The second method included lysis of cell
monolayers in lysis reagent, homogenization in QIAshredder spin
columns, and further processing according to the manufacturer's instructions (RNeasy; QIAGEN Inc.). The concentration of RNA was determined by measuring the optical density at 260 nm. One microgram of
the extracted total RNA per 20-µl reaction volume was used for
reverse transcription (RT) according to manufacturer's instructions (Reverse Transcription System kit; Promega, Madison, Wis.). Between 2 and 8 µl of cDNA was used for each PCR. The cycle conditions were 1 min at 94°C, 1 min at 66°C, and 1 min at 72°C for 27 to 30 amplification cycles. The number of amplification cycles used was
chosen based on maintenance of linearity of the PCR product response.
Verification that the amplified PCR products originated from RNA rather
than DNA was accomplished by preparing duplicate RNA samples without
the reverse transcriptase step, followed by PCR amplification and
visualization on agarose gels. Lack of products ensured that potential
DNA contamination was absent.
For Northern blotting, 10 to 20 µg of total RNA was separated on
glyoxal agarose gels and transferred to nylon membranes according to
the manufacturer's instructions (NorthernMax Gly; Ambion, Inc., Austin, Tex.). IL-8 template DNA, a kind gift from Edouard Vannier, corresponds to IL-8 gene exon sequences from +38 in exon 1 to the
EcoRI site in exon 4. This template DNA was subcloned, and an RNA probe was synthesized by using T3 polymerase and modified CTP
according to the manufacturer's instructions (Strip-EZ RNA; Ambion,
Inc.). A glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe
was isolated from ATCC plasmid 57090. A probe for c-jun mRNA
was synthesized as a 352-bp product by using previously described primers (14). Probes were labeled by cross-linking with
psoralen-biotin and detected by chemiluminescence according to the
manufacturer's instructions (BrightStar labeling and detection kits;
Ambion, Inc.). Blots were hybridized overnight with the IL-8 probe at 65°C, the c-jun probe at 52°C, or the GAPDH probe at
45°C, followed by washing and detection. Bands were quantitated by
scanning densitometry and use of QuantityOne software (Bio-Rad,
Hercules, Calif.).
 |
RESULTS |
Effects of Stx1 and Stx2 on secretion of IL-8 by Hct-8 cells.
Addition of Stx1 or Stx2 to Hct-8 cells caused an increase in IL-8
secretion. The dose response of IL-8 protein secreted from Hct-8 cells
incubated with various amounts of Stx1 or Stx2 for 18 h is shown
in Fig. 1. The data shown are mean IL-8
levels and standard deviations (SD) for three to six wells per
condition from a single representative experiment; at least three
experiments demonstrated results similar to those shown in Fig. 1,
though there was some variability in total IL-8 produced from
experiment to experiment based on age and plating density of cells. In
the experiment shown, unstimulated Hct-8 cells secreted 475 ± 101 pg of IL-8 per ml into cell supernatants after 18 h. Stx1 and Stx2
increased IL-8 secretion to a maximum of approximately 3.6-fold over
control levels in a dose-dependent way. The potencies of Stx1 and Stx2
were similar; both stimulated increased IL-8 secretion into cell
supernatants at doses of 10 ng/ml and higher. Exposure to Stx1 at 100 µg/ml and Stx2 at 100 µg/ml resulted in mean IL-8 levels in cell
supernatants of 1,680 ± 9 and 1,702 ± 24 pg/ml, respectively. Stx1 and Stx2 inactivated by boiling did not stimulate IL-8 secretion above control levels. Purified Stx1 B (binding) subunit
did not increase the amount of IL-8 protein found in conditioned media
(data not shown).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Secretion of IL-8 by Hct-8 cells treated with Stxs for
18 h. For each concentration of Stx1 (A) or Stx2 (B), IL-8
measured in cell culture supernatants is shown (means ± SD from
three to six wells). Solid bars represent native toxin; hatched bars
represent boiled toxin. Inserted above each solid bar is mean protein
synthesis expressed as a percentage of control (no toxin) levels, as
determined by [3H]leucine incorporation at the end of the
incubation. (SD are reported in parentheses.) Comparisons between
Stx-induced IL-8 levels and control levels were calculated.
P values are as follows: *, 0.009; **, 0.012.
|
|
Association between inhibition of protein synthesis by Stxs in
Hct-8 cells and IL-8 secretion.
To investigate whether synthesis
of IL-8 by Hct-8 cells was correlated with the known mechanism of
action of Stx (inhibition of protein synthesis), we measured IL-8
synthesis by Hct-8 cells as a function of protein synthesis inhibition,
using a range of doses as well as several doses over time. Figure 1
shows the percentage of protein synthesis inhibition achieved by a
given amount of Stx1 or Stx2 as measured at the end of incubation (18 h
after addition of toxin). Increasing amounts of Stx1 and Stx2 result in
increasing inhibition of protein synthesis. As shown in Fig. 1A, Stx1
at a dose of 1 ng/ml inhibited protein synthesis to 86% of control
levels but did not increase the levels of IL-8 secreted into cell
supernatants. Stx1 began to affect IL-8 secretion into cell
supernatants at a dose of 10 ng/ml, which reduced protein synthesis to
79% of control levels. As protein synthesis was further inhibited by
increasing amounts of Stx1, increasing amounts of IL-8 were secreted
into cell supernatants. In this representative experiment, the highest
amounts of IL-8 were secreted into cell supernatants when protein
synthesis was reduced to just 1 to 3% of control levels for Stx1; in
other experiments, the effect of Stx1 on protein synthesis at these
doses was less, in the 30 to 40% range, but with an increase in IL-8
secretion similar to that shown in Fig. 1A.
Stx2 had similar effects, as shown in Fig. 1B. Stx2 at 1 ng/ml had no
significant effect on protein synthesis (97% ± 2% of control
levels), and no increased IL-8 was demonstrated in cell supernatants.
At 10 ng/ml, Stx2 inhibited protein synthesis to 93% of control levels
and an increase in IL-8 in cell supernatants was demonstrated. At 10 µg of Stx2 per ml, protein synthesis was inhibited to 48% of control
levels and a 3.6-fold increase in IL-8 protein secreted into cell
supernatants was seen.
The phenomenon of increasing amounts of IL-8 synthesis despite
reductions in overall protein synthesis due to Stxs raised the question
of whether Stxs were inducing IL-8 expression soon after toxin exposure
and IL-8 was being secreted by cells prior to an effect on protein
synthesis. A time course experiment was therefore undertaken with
several doses of Stx. As the single-time-point experiments showed no
difference between Stx1 and Stx2 and the appearance of IL-8 in the
medium was similar for both toxins, we used Stx2 in the time course
experiment. At various times during incubation, cell supernatants were
harvested for IL-8 protein level determinations, and protein synthesis
inhibition was measured by [3H]leucine incorporation.
These data are shown in Fig. 2. Figure 2A
shows that IL-8 secretion by Stx2-treated Hct-8 cells begins to diverge
from control levels by 12 h and thereafter increases steadily over
time throughout the remainder of the incubation. As before, we saw the
toxin dose response effect on IL-8 secretion. Figure 2B shows the
percentage of protein synthesis inhibition following exposure to three
doses of Stx2. By 4 h of exposure, all doses of Stx2 significantly
reduced protein synthesis, and this preceded the increase of IL-8 in
cell supernatants.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 2.
Association between inhibition of protein synthesis with
Stx2 in Hct-8 cells and IL-8 synthesis over time. (A) IL-8 secretion
into cell supernatants over time with various doses of Stx2.
Comparisons were made between Stx2-induced IL-8 levels and control
levels. P values are as follows: *, NS; ** (for 10 µg/ml), <0.0001; ** (1 µg/ml), 0.0002; ** (100 ng/ml),
0.0002. (B) Inhibition of protein synthesis over time following
exposure to various doses of Stx2. Each point represents mean ± SD from three wells. #, significant P value of 0.02 for
10-µg/ml dose of Stx2; ##, P values for all doses at this
time point are <0.03. P values for 1 µg/ml and 100 ng/ml
are not significant.
|
|
Effects of Stxs on TNF-
-stimulated IL-8 protein and mRNA levels
in Hct-8 cells.
TNF-
is a potent inducer of the chemokine IL-8
from many cells, including Hct-8 cells. We treated cells with Stx1 at a
range of doses, TNF-
at a single dose of 10 ng/ml, or a combination of Stx1 with TNF-
to determine if Stx1 was capable of causing an
enhancement in IL-8 secretion above that seen with TNF-
alone. TNF-
alone caused a much higher IL-8 level in cell supernatants than
did Stx1 alone (Fig. 3). When TNF-
and
Stx1 were added together, the treatment resulted in higher levels of
IL-8 secreted into culture supernatants than those expected from
additive effects of either substance alone (Fig. 3). For example, cells
treated with Stx1 alone at 1 µg/ml secreted 774 pg of IL-8 per ml and cells treated with TNF-
alone secreted 6,855 pg of IL-8 per ml, but
cells treated with both Stx1 at 1 µg/ml and TNF-
secreted 9,320 pg
of IL-8 per ml. Stx-mediated protein synthesis inhibition measured at
the end of incubation was not affected by the presence of TNF-
(Fig.
3).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Secretion of IL-8 by Hct-8 cells treated with Stx1,
TNF- , or both. For each concentration of Stx1 alone, TNF- alone,
or Stx1 plus TNF- , IL-8 measured in cell culture supernatants is
shown (mean amounts from three to six samples with SD). Inserted above
each solid bar is protein synthesis expressed as a percentage of
control levels, as determined by [3H]leucine
incorporation (SD are reported in parentheses). Comparisons were made
between TNF- -induced IL-8 levels and Stx1-plus-TNF- -induced IL-8
levels. P values are as follows: *, 0.0002; **,
<0.0001; #, 0.001; ##, 0.0005.
|
|
We used semiquantitative RT-PCR to determine whether IL-8 mRNA levels
were increased in cells treated with Stxs. Total cellular RNA was
extracted from Hct-8 cells exposed to either Stx1 (100 ng/ml), Stx2
(100 ng/ml), Stx1 B subunit (100 ng/ml), TNF-
, heat-inactivated Stxs
(100 ng/ml), or control for 6 h, as described in Materials and
Methods. Equal amounts of total RNA from each sample were subjected to
RT-PCR analysis with specific human IL-8 and
-actin primers,
generating 289- and 661-bp fragments, respectively. Figure 4 shows that IL-8 mRNA was present in
increased amounts in cells treated with either Stx1 or Stx2. As
expected, TNF-
increased IL-8 mRNA levels above control levels, and
heat-inactivated Stx1 or Stx2 and Stx1 B subunit did not have a
significant effect.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 4.
Effects of Stx1, Stx2, and TNF- on IL-8 mRNA. Shown
is an ethidium bromide-stained 1.5% agarose gel following RT-PCR
analysis of total cellular RNA extracted from Hct-8 cells exposed to
either Stx1 (100 ng/ml), Stx2 (100 ng/ml), heat-inactivated Stx1 and
Stx2 at similar concentrations, Stx1 B subunit (100 ng/ml), TNF- (10 ng/ml), or control (no additives) for 6 h, as described in
Materials and Methods. Human IL-8 and -actin primers generated
fragments of 289 and 661 bp, respectively. Lanes are as follows: 1, control; 2, Stx1; 3, Stx2; 4, heat-inactivated Stx1; 5, heat-inactivated Stx2; 6, Stx1 B subunit; 7, TNF- . The image shown
was scanned with an Agfa Arcus II scanner and Fotolook SA.
|
|
Figure 5 shows IL-8 mRNA as detected by
Northern blotting. IL-8 mRNA levels increased over control levels after
6 h of incubation with TNF-
. When cells were stimulated with
TNF-
in the presence of Stx1, levels of IL-8 mRNA increased
dramatically over levels seen with TNF-
alone. Significant induction
of IL-8 mRNA was also observed when cells were treated with Stx1 and
Stx2 alone; it was approximately 5- to 10-fold over IL-8 mRNA induction
due to TNF-
alone. Interestingly, although both Stxs and TNF-
increase IL-8 message, TNF-
results in a much greater increase in
IL-8 protein levels (Fig. 3).

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 5.
Superinduction of IL-8 mRNA with TNF- and Stx1. Shown
is a Northern blot of total cellular RNA extracted from Hct-8 cells
exposed to TNF- (10 ng/ml), Stx1 (1 µg/ml), Stx2 (1 µg/ml), or
TNF- and Stx1 (10 ng/ml and 1 µg/ml, respectively). The upper
panel shows the results with an IL-8 probe; the lower panel shows the
results with a GAPDH probe as a housekeeping gene.
|
|
Association between inhibition of protein synthesis by
cycloheximide in Hct-8 cells and IL-8 secretion.
To determine if
the effect of increased IL-8 secretion with increasing protein
synthesis inhibition was specific to Stxs or if inhibition of protein
synthesis resulted in cells releasing stored IL-8, another protein
synthesis inhibitor that acts on the ribosome, cycloheximide, was used
to inhibit protein synthesis to similar levels in a time course
experiment (Fig. 6). Two doses of
cycloheximide were used (100 µg/ml and 1 mg/ml). Figure 6A shows that
both doses of cycloheximide resulted in decreased amounts of IL-8
secreted into cell supernatants, as would be typically expected from
blockade of translation. The degrees of protein synthesis inhibition
with the two doses of cycloheximide (Fig. 6B) were similar to those
with the Stx doses used in the experiment shown in Fig. 2B.
Cycloheximide begins to affect cells within 2 h of exposure, and
IL-8 levels in the cell supernatants decrease to levels below control
by 12 to 16 h and remain lower than control levels throughout the
remainder of incubation. Doses of cycloheximide (5 mg/ml) that resulted
in complete cell death and obvious disruption of the monolayer (as
visualized by microscopy) had extremely low levels of IL-8 (data not
shown).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 6.
Association between inhibition of protein synthesis with
cycloheximide (CHX) in Hct-8 cells and IL-8 synthesis over time. (A)
IL-8 secretion into cell supernatants over time with two doses of
cycloheximide. (B) Inhibition of protein synthesis over time following
exposure to the same two doses of cycloheximide. Each point represents
the mean ± SD from three wells.
|
|
Effects of other protein synthesis inhibitors on IL-8 secretion and
overall protein synthesis.
The effects of 18 h of exposure to
various protein synthesis inhibitors on IL-8 secretion are shown in
Fig. 7. Ricin has the same enzymatic action as Stx; at doses of 1 and 10 pg/ml, ricin had no
effect on IL-8 secretion (Fig. 7A). At a dose of 100 pg/ml, which
reduced protein synthesis to 78% of control, IL-8 secreted into cell
supernatants was elevated 1.8-fold over baseline levels. When ricin was
increased to 1 ng/ml, which inhibited protein synthesis to 8% ± 3%
of control levels, IL-8 secreted into cell supernatants was elevated
3.5-fold above control levels. Like Stxs, increasing doses of ricin
result in increasing amounts of IL-8 being secreted into cell
supernatants, despite a concurrent inhibition of total protein
synthesis. Ricin is more potent than Stx1 or Stx2 in inhibiting protein
synthesis, with an ID50 of 0.1 to 1 ng/ml, compared to Stx1, which has an ID50 of approximately 1 µg/ml, but
achieved a similar increase in IL-8 secretion over control levels
(3.5-fold versus 3.6-fold over control) at comparable levels of protein synthesis (8% versus 1%).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 7.
Secretion of IL-8 by Hct-8 cells treated with
various protein synthesis inhibitors. The data shown are from a single
representative experiment; several experiments undertaken with each
inhibitor showed similar results (two experiments for ricin [A],
three for anisomycin [B], and three for cycloheximide [C]). For
each protein synthesis inhibitor, IL-8 (mean amounts from three to six
wells with SD) measured in cell culture supernatants is shown after
18 h of exposure to the different inhibitors. Control experiments
were performed with no drug. Inserted above each solid bar is mean
protein synthesis expressed as a percentage of control levels, as
determined by [3H]leucine incorporation (SD are reported
in parentheses).
|
|
Anisomycin at 5 and 10 ng/ml had a minimal effect on protein synthesis
inhibition (Fig. 7B) and slightly but significantly increased IL-8
secretion into cell supernatants over control levels (P of
0.003 and 0.01, respectively). Anisomycin at 50 ng/ml resulted in
increased IL-8 secretion by a 2.0-fold increase over control levels and
inhibited protein synthesis to 62% of control levels. Increasing doses
of anisomycin resulted in a further increase of IL-8 secretion into
cell supernatants without further reducing overall protein synthesis
inhibition. The maximum effect on IL-8 secretion was at a dose of 500 ng/ml, which resulted in IL-8 secretion into cell supernatants of 1,979 pg/ml (3.3-fold over control) and protein synthesis inhibition to 62%
of baseline levels. Increasing doses beyond this point resulted in a
progressive decline from the maximum effect on IL-8 secreted into
supernatants with a minimal fall in overall protein synthesis (Fig.
7B).
Figure 7C shows results for various doses of cycloheximide. The control
cells secreted 340 pg of IL-8 per ml into cell supernatants. In this
example, any dose of cycloheximide that inhibited protein synthesis
decreased the amount of IL-8 secreted into cell supernatants in a
dose-dependent fashion, until doses that killed the Hct-8 epithelial
cell monolayers were reached (in this case, a dose of 5 mg/ml [not
shown]). There was a paradoxical effect of cycloheximide at 10 µg/ml, which appeared to increase IL-8 secretion. In the experiment
shown, protein synthesis appeared to be stimulated to 124% of control,
but this ranged from 86 to 124% for the stimulatory doses of
cycloheximide in the three experiments undertaken. However, low-dose
cycloheximide significantly increased IL-8 expression in all three
experiments, with increases ranging from 1.3- to 1.6-fold over control
and P values ranging from 0.02 to 0.04.
Effect of SB202190 on Stx-induced IL-8 secretion.
Anisomycin
has been associated with induction of primary response genes in
mammalian cells by activation of several members of MAPK family
cascades (reviewed in reference 12). We used the
specific p38 kinase inhibitor SB202190 (21) to determine if
the p38/RK kinase pathway may be involved in Stx-induced IL-8 secretion. Figure 8 is representative of
at least three different experiments and shows the effect of SB202190
on IL-8 secretion from Stx1-treated Hct-8 cells. IL-8 was slightly but
significantly decreased in SB202190-treated controls compared to
medium-only controls. As expected, SB202190 decreased
anisomycin-induced IL-8 secretion significantly, but not completely,
compared to SB202190-only controls. This is consistent with previous
reports that anisomycin activates multiple MAPKs, including SAPK/JNK1
and multiple kinases in the p38/RK cascade (12). As
treatment with a specific p38 inhibitor does not affect SAPK/JNK1
activity, a smaller amount of IL-8 is secreted in the presence of
anisomycin plus SB202190. In contrast, at Stx1 doses of 10 µg/ml and
below, SB202190 decreased IL-8 secretion to levels that were not
significantly different from SB202190-only controls. In some
experiments using 10 µg of Stx1 per ml plus inhibitor, IL-8 secretion
was diminished but still significantly higher than control levels,
similar to our observations with anisomycin (data not shown). In the
absence of SB202190, Stx1 increased IL-8 to levels significantly above medium-only controls (P values ranging from 0.02 to 0.0003).
Measurements of inhibition of protein synthesis by Stxs in the presence
or absence of SB202190 were not significantly different (data not shown).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 8.
Secretion of IL-8 by Hct-8 cells in the presence of the
p38/RK inhibitor SB202190. The data shown are from a single
representative experiment; at least three experiments showed similar
results. For each dose of Stx1 or anisomycin, IL-8 (mean amounts from
three to six wells with SD) measured in cell culture supernatants is
shown after 18 h of exposure in the presence or absence of
SB202190. Hatched bars show results with SB202190; solid bars show
results without SB202190. Control experiments used no Stx or
anisomycin. P values are as follows: *, 0.02; **,
0.001; ***, 0.003; #, 0.0003; ##, 0.002; NS, not significant.
|
|
Effects of Stxs on induction of c-jun mRNA.
As
both anisomycin and ricin are associated with induction of SAPK/JNK1
and induction of mRNA from the primary response genes c-fos
and c-jun (15), we hypothesized that Stxs may
also induce c-jun mRNA. We used Northern blotting to
determine whether c-jun mRNA was increased in cells treated
with Stxs. Hybridization of total RNA with a c-jun specific
probe detects two bands as a result of alternate polyadenylation
signals utilized in the processing of primary c-jun
transcripts (4). Figure 9
shows that c-jun mRNA is present in increased amounts in
cells treated with either Stx1 or Stx2 at 1 µg/ml (lanes 2 and 8, respectively) compared to control (lane 1). Heat-inactivated Stx1 at 1 µg/ml (lane 3) did not have a significant effect. Treatment with the
p38/RK inhibitor SB202190 diminished the induction of c-jun
mRNA in response to Stx1 and Stx2 (lanes 5 and 9, respectively).
SB202190 alone did not have a significant effect on c-jun
mRNA (lane 4). As expected, anisomycin also induced c-jun
mRNA (lane 6), an effect that does not appear to be significantly
diminished by treatment with SB202190 (lane 7).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 9.
Effects of Stx1 and Stx2 on c-jun mRNA in the
presence and absence of SB202190. Shown is a Northern blot of total
cellular RNA extracted from Hct-8 cells exposed to Stx1 (1 µg/ml),
heat-inactivated Stx1 (1 µg/ml), Stx2 (1 µg/ml), or anisomycin (500 ng/ml) in the presence and absence of SB202190 or SB202190 diluent. The
upper panel shows the results with a c-jun probe; the lower
panel shows the results with a GAPDH probe as a housekeeping gene.
Lanes are as follows: 1, diluent control; 2, Stx1; 3, heat-inactivated
Stx1; 4, SB202190; 5, Stx1 + SB202190; 6, anisomycin; 7, anisomycin + SB202190; 8, Stx2; 9, Stx2 + SB202190.
|
|
 |
DISCUSSION |
Stxs have been thought to cause disease by killing or irreversibly
harming sensitive cells by a nonspecific blockade of mRNA translation,
eventually resulting in cytotoxicity as critical molecules needed to
maintain cell integrity are no longer produced. The present data
suggest a novel and different model of how Stxs may contribute to
disease, namely, that Stxs alter regulation of host cell processes in
sensitive intestinal epithelial cells. We have found that despite
increasing general blockade of mRNA translation, Stx treatment results
in the apparent paradox of increased synthesis and secretion of IL-8
protein by a human colonic epithelial cell line without affecting cell
integrity. This response is not due to contaminating lipopolysaccharide
in the Stx preparations, as Stxs inactivated by boiling or Stx1 B
subunit alone did not stimulate IL-8 secretion above baseline. Thus, an
enzymatically active Stx A subunit appears to be required for this
response, an idea that is supported by recent work from Yamasaki et al. (37), who show that Stxs increase IL-8 from Caco-2 cells and that this is dependent on the toxin being biologically active. The
increase in secretion of IL-8 protein into cell supernatants is not due
to cell destruction with subsequent release of stored IL-8, as doses of
cycloheximide that disrupted cell monolayers did not result in
increased levels of IL-8 protein. This is consistent with the data
demonstrating that IL-8 production is generally not constitutive but
inducible and regulated at the level of gene transcription
(25). These data suggest that the IL-8 secreted into cell
supernatants is newly synthesized. How Stxs may exert an inhibitory
effect on overall protein synthesis and yet allow for synthesis of the
chemokine IL-8 is unknown. We (3), as well as others
(16, 37), have shown previously that Stxs can stimulate
chemokine synthesis in different intestinal epithelial cell lines (T84,
Caco-2), suggesting that IL-8 synthesis by colonic epithelial cells
exposed to Stx is not a unique property of the Hct-8 epithelial cell
line described and utilized in these experiments.
Stxs increase IL-8 mRNA levels, as well as secreted IL-8 protein, in
Hct-8 cells. As demonstrated by Northern blotting, the IL-8 mRNA levels
found in response to Stxs is increased above amounts seen with the
known IL-8 inducer TNF-
. Moreover, following exposure to Stxs there
is a higher relative IL-8 mRNA/IL-8 protein ratio than that following
TNF-
stimulation. This finding suggests that Stxs are either causing
a partial translational block, enhancing mRNA stability, or both. As
demonstrated by Northern blotting, Stx1 augmented the amount of IL-8
mRNA as well as IL-8 protein secreted by Hct-8 cells in response to
TNF-
, reaching levels above those expected from additive effects of
either substance alone. It is clear from these results that in Hct-8
cells, Stxs are capable of induction and superinduction of IL-8, at
both the mRNA and protein levels.
The superinduction phenomenon has been described previously with other
protein synthesis inhibitors, whereby a protein synthesis inhibitor
added along with an inducing factor can lead to massive overaccumulation of mRNA transcripts of certain primary response genes,
including cytokines (7, 29). It is also known that protein
synthesis inhibitors alone can independently stimulate primary response
gene expression. Several hypotheses have been proposed to explain how
protein synthesis inhibitors cause induction and superinduction effects
(9, 38), but the exact mechanism(s) by which protein
synthesis inhibitors cause these effects is unknown, and multiple
mechanisms may contribute. In one study, cycloheximide increased IL-8
mRNA levels in lung epithelial cells by modifying both transcriptional
activator activity and mRNA stability (29). These questions
are currently under study in our laboratory.
The ability of Hct-8 cells to secrete IL-8 after treatment with protein
synthesis inhibitors appears to be generalizable to other protein
synthesis inhibitors acting on different steps in translation of mRNA:
elongation factor-associated steps (Stx and ricin), peptide bond
formation (anisomycin), or multiple steps (cycloheximide, acting on
initiation, elongation, and termination). The similarities between IL-8
secretion due to Stxs, anisomycin, and ricin led us to explore the
effects of Stxs as possible inducers of MAPK family cascades.
Previously, anisomycin and ricin have been associated with a response
termed the "ribotoxic stress response" (15). The
ribotoxic stress response is induced following damage to the 28S rRNA
by either anisomycin or ricin, resulting in induction of SAPK/JNK1 and
induction of mRNAs of the primary response genes c-fos and
c-jun. Anisomycin has also been associated with induction of
primary response genes in mammalian cells by activation of the p38/RK
cascade (reviewed in reference 12). We have shown that Stxs can induce and superinduce IL-8. Stx-mediated induction of
IL-8 protein occurs via a mechanism that is strongly inhibited by the
p38/RK specific inhibitor SB202190. Furthermore, we have demonstrated
that Stxs can induce c-jun mRNA and that this induction can
be diminished by SB202190. These data suggest that Stxs act to induce
mRNAs from primary response genes via a mechanism similar to the
ribotoxic stress response involving activation of the p38/RK cascade.
Our data with residual IL-8 induction by Stx1 at high doses (10 µg/ml) in the presence of SB202190 and residual c-jun induction by Stx1 and Stx2 in the presence of SB202190 suggest that
other MAPK cascades may be involved in this response at high doses.
There are data to suggest that, in the case of anisomycin, the
SAPK/JNK1 cascade is strongly implicated in induction of
c-jun but that the ERK1/2 cascade is not (6). We
are presently exploring Stx effects on SAPK/JNK1 activity.
The presence of proinflammatory cytokines such as TNF-
(20) and IL-8 (34) in the serum of some patients
with diarrhea-associated HUS has been demonstrated. Proinflammatory
cytokines appear to be locally produced in colitis due to
Shigella species (27), and stool TNF-
and IL-8
levels were found to be higher in patients infected with the
Stx-producing Shigella dysenteriae type 1 than in patients
with dysentery due to the non-Stx-producing Shigella flexneri (28). Stxs have recently been reported to
activate TNF-
gene transcription and nuclear translocation of
NF-
B and AP-1 in human monocytes (30). On the basis of
these data, it has been suggested that Stxs may engage in
cell-signaling activities with various human cells, resulting in
proinflammatory cytokine synthesis. In our study, cytokine synthesis
was triggered by doses of Stxs that may be attained in the
gastrointestinal tract during human infection (1). It may be
that the inflammatory response to STEC is initiated in the
gastrointestinal mucosa and submucosa where host cells are first
exposed to the high levels of Stxs found in the intestine. We know that
certain enteropathogenic E. coli strains can stimulate
activation of NF-
B, production of IL-8, and neutrophil migration
(32). A critical role of Stxs may be to augment the cytokine
synthesis response to infection in the milieu of the submucosa, from
which STEC strains are excluded. Chemokines synthesized in the
submucosal areas may allow enhanced recruitment and activation of
inflammatory cells with subsequent compromise of the intestinal
barrier, thereby potentially increasing systemic absorption of Stxs and
subsequent initiation of systemic complications.
In summary, these data show that Stxs can alter regulation of host cell
processes, leading to a paradoxical increase in the synthesis of
specific proteins. The mechanism by which this is mediated is not yet
known, but it appears to include activation of the p38/RK cascade and
induction of c-jun mRNA. We hypothesize that Stxs act in a
fashion similar to anisomycin and ricin, damaging the 28S rRNA and
inducing the ribotoxic stress response with subsequent initiation of
signal transduction, activation of a MAPK family member(s), and
induction of mRNAs of immediate-early genes such as
c-jun and IL-8.
 |
ACKNOWLEDGMENTS |
Research support for this study includes the following grants
from the National Institutes of Health (NIH), Bethesda, Md.: HL-55660,
A1-16242, A1-39067, and P 30 DK-34928 for the Center for
Gastroenterology Research on Absorptive and Secretory Processes. C. M. Thorpe was supported by NIH training grant T32-A1-07329.
We thank Thao N. Ngo and Jonathan L. Rubinstein for expert technical assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Geographic Medicine and Infectious Diseases, New England Medical
Center, Box 041, 750 Washington St., Boston, MA 02111. Phone: (617)
636-7002. Fax: (617) 636-5292. E-mail:
david.acheson{at}es.nemc.org.
Editor:
J. R. McGhee
 |
REFERENCES |
| 1.
|
Acheson, D. W. K.,
S. D. De Breucker,
A. Donahue-Rolfe,
K. Kozak,
A. Yi, and G. T. Keusch.
1994.
Development of a clinically useful diagnostic enzyme immunoassay for enterohemorrhagic Escherichia coli infection, p. 109-112.
In
M. A. Karmali, and A. G. Goglio (ed.), Recent advances in verocytotoxin-producing E. coli infections. Elsevier Science, Amsterdam, The Netherlands.
|
| 2.
|
Acheson, D. W. K.,
R. Moore,
S. De Breucker,
L. Lincicome,
M. Jacewicz,
E. Shutelsky, and G. T. Keusch.
1996.
Translocation of Shiga toxins across polarized intestinal cells in tissue culture.
Infect. Immun.
64:3294-3300[Abstract].
|
| 3.
|
Acheson, D. W. K.
1996.
Effect of Shiga toxins on cytokine production from intestinal epithelial cells, p. 67-73.
In
G. T. Keusch, and M. Kawakami (ed.), Cytokines, cholera, and the gut. IOS Press, Amsterdam, The Netherlands.
|
| 4.
|
Angel, P.,
E. A. Allegretto,
S. T. Okino,
K. Hattori,
W. J. Boyle,
T. Hunter, and M. Karin.
1988.
Oncogene jun encodes a sequence-specific trans-activator similar to AP-1.
Nature
332:166-171[Medline].
|
| 5.
|
Blake, D. C. I.,
R. G. Russell,
E. Santini,
T. Bowen, and E. C. Boedeker.
1996.
Pro-inflammatory mucosal cytokine responses to Shiga-like toxin-1 (SLT-1), p. 75-82.
In
G. T. Keusch, and M. Kawakami (ed.), Cytokines, cholera, and the gut. IOS Press, Amsterdam, The Netherlands.
|
| 6.
|
Cano, E.,
C. A. Hazzalin, and L. C. Mahadevan.
1994.
Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun.
Mol. Cell. Biol.
14:7352-7362[Abstract/Free Full Text].
|
| 7.
|
Edwards, D. R., and L. C. Mahadevan.
1992.
Protein synthesis inhibitors differentially superinduce c-fos and c-jun by three distinct mechanisms: lack of evidence for labile repressors.
EMBO J.
11:2415-2424[Medline].
|
| 8.
|
Elliott, E.,
L. Zhe,
C. Bell,
D. Stiel,
A. Buret,
J. Wallace,
I. Brzuszczak, and E. O'Loughlin.
1994.
Modulation of host response to Escherichia coli O157:H7 infection by anti-CD18 antibody in rabbits.
Gastroenterology
106:1554-1561[Medline].
|
| 9.
|
Faggioli, L.,
C. Constanzo,
M. Merola,
A. Furia, and M. Palmieri.
1997.
Protein synthesis inhibitors cycloheximide and anisomycin induce interleukin-6 gene expression and activate transcription factor NF- B.
Biochem. Biophys. Res. Commun.
233:507-513[Medline].
|
| 10.
|
Griffin, P. M.,
S. M. Ostroff,
R. V. Tauxe,
K. D. Greene,
J. G. Wells,
J. H. Lewis, et al.
1988.
Illnesses associated with Escherichia coli O157:H7 infections. A broad clinical spectrum.
Ann. Intern. Med.
109:705-712.
|
| 11.
|
Grisham, M. B., and D. N. Granger.
1988.
Neutrophil-mediated mucosal injury: role of reactive oxygen metabolites.
Dig. Dis. Sci.
33:6S-15S[Medline].
|
| 12.
|
Hazzalin, C. A.,
R. Le Panse,
E. Cano, and L. C. Mahadevan.
1998.
Anisomycin selectively desensitizes signalling components involved in stress kinase activation and fos and jun induction.
Mol. Cell. Biol.
18:1844-1854[Abstract/Free Full Text].
|
| 13.
| Hurley, B. P., C. M. Thorpe, and D. W. K. Acheson. Unpublished data.
|
| 14.
|
Ikawa, T.,
M. Ikeda,
A. Yamaguchi,
W. C. Tsai,
N. Tamura,
N. Seta,
M. Trucksess,
R. B. Raybourne, and D. T. Y. Yu.
1998.
Expression of arthritis-causing HLA-B27 on HeLa cells promotes induction of c-fos in response to in vitro invasion by Salmonella typhimurium.
J. Clin. Investig.
101:263-272[Medline].
|
| 15.
|
Iordanov, M.,
D. Pribnow,
J. L. Magun,
T.-H. Dinh,
J. A. Pearson,
S. L. Chen, and B. E. Magun.
1997.
Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the -sarcin/ricin loop in the 28S rRNA.
Mol. Cell. Biol.
17:3373-3381[Abstract].
|
| 16.
|
Ismaili, A.,
D. J. Philpott,
D. M. McKay,
M. H. Perdue, and P. M. Sherman.
1998.
Epithelial cell responses to Shiga toxin-producing Escherichia coli infection, p. 213-225.
In
J. B. Kaper, and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, D.C.
|
| 17.
|
Jacewicz, M.,
H. A. Feldman,
A. Donohue-Rolfe,
K. A. Balasubramanian, and G. T. Keusch.
1989.
Pathogenesis of Shigella diarrhea. XIV. Analysis of Shiga toxin receptors on cloned HeLa cells.
J. Infect. Dis.
159:881-889[Medline].
|
| 18.
|
Jung, H. C.,
L. Eckmann,
S. Yang,
A. Panja,
J. Fierer,
E. Morzycka-Wroblewska, and M. F. Kagnoff.
1995.
A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion.
J. Clin. Investig.
95:55-65.
|
| 19.
|
Karmali, M. A.,
M. Petric,
C. Lim,
P. C. Fleming,
G. S. Arbus, and H. Lior.
1985.
The association between idiopathic hemolytic uremic syndrome and infection by verocytotoxin-producing Escherichia coli.
J. Infect. Dis.
151:775-782[Medline].
|
| 20.
|
Karpman, D.,
A. Andreasson,
H. Thysell,
B. S. Kaplan, and C. Svanborg.
1995.
Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenia purpura.
Pediatr. Nephrol.
9:694-699[Medline].
|
| 21.
|
Lee, J. C., and P. R. Young.
1996.
Role of CSBP/p38/RK stress response kinase in LPS and cytokine signalling mechanisms.
J. Leukoc. Biol.
59:152-157[Abstract].
|
| 22.
|
Li, Z.,
C. Bell,
A. Buret,
R. Robins-Browne,
D. Stiel, and E. V. O'Laughlin.
1993.
The effect of enterohemorrhagic Escherichia coli O157:H7 on intestinal structure and solute transport in rabbits.
Gastroenterology
104:467-474[Medline].
|
| 23.
|
Lieberman, E.,
E. Heuser,
G. N. Donnell,
B. H. Landing, and G. D. Hammond.
1966.
Hemolytic uremic syndrome. Clinical and pathological considerations.
N. Engl. J. Med.
275:227-236.
|
| 24.
|
Nataro, J. P., and J. B. Kaper.
1998.
Diarrheagenic Escherichia coli.
Clin. Microbiol. Rev.
11:142-201[Abstract/Free Full Text].
|
| 25.
|
Okamoto, S.,
N. Mukaida,
K. Yasumoto,
H. Horiguchi, and K. Matsushima.
1993.
Molecular mechanism of interleukin-8 gene expression, p. 87-97.
In
I. J. D. Lindley, et al. (ed.), The chemokines. Plenum Press, New York, N.Y.
|
| 26.
|
Paton, J. C., and A. W. Paton.
1998.
Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections.
Clin. Microbiol. Rev.
11:450-479[Abstract/Free Full Text].
|
| 27.
|
Raqib, R.,
A. A. Lindberg,
B. Wretlind,
P. K. Bardhan,
U. Andersson, and J. Andersson.
1995.
Persistence of local cytokine production in shigellosis in acute and convalescent stages.
Infect. Immun.
63:289-296[Abstract].
|
| 28.
|
Raqib, R.,
B. Wretlind,
J. Andersson, and A. A. Lindberg.
1995.
Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma.
J. Infect. Dis.
171:376-384[Medline].
|
| 29.
|
Roger, T.,
T. Out,
N. Mukaida,
K. Matsushima,
H. Jansen, and R. Lutter.
1998.
Enhanced AP-1 and NF- B activities and stability of interleukin 8 (IL-8) transcripts are implicated in IL-8 mRNA superinduction in lung epithelial H292 cells.
Biochem. J.
330:429-435.
|
| 30.
|
Sakiri, R.,
B. Ramegowda, and V. L. Tesh.
1998.
Shiga toxin type 1 activates tumor necrosis factor- gene transcription and nuclear translocation of the transcriptional activators nuclear factor- B and activator protein-1.
Blood
92:558-566[Abstract/Free Full Text].
|
| 31.
|
Savkovic, S. D.,
A. Koutsouris, and G. Hecht.
1996.
Attachment of a noninvasive enteric pathogen, enteropathogenic Escherichia coli, to cultured human intestinal epithelial monolayers induces transmigration of neutrophils.
Infect. Immun.
64:4480-4487[Abstract].
|
| 32.
|
Savkovic, S. D.,
A. Koutsouris, and G. Hecht.
1997.
Activation of NF- B in intestinal epithelial cells by enteropathogenic Escherichia coli.
Am. J. Physiol.
273:C1160-C1167.
|
| 33.
|
Slutsker, L.,
A. A. Ries,
K. D. Greene,
J. G. Wells,
L. Hutwagner, and P. M. Griffin.
1997.
Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features.
Ann. Intern. Med.
126:505-513[Abstract/Free Full Text].
|
| 34.
|
van Setten, P.,
V. van Hinsbergh,
L. van den Heuvel,
F. Preyers,
H. Dijkman,
K. Assmann,
T. van der Velden, and L. Monnens.
1998.
Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patients with hemolytic uremic syndrome.
Pediatr. Res.
43:759-767[Medline].
|
| 35.
|
Wallace, J. L.,
A. Higa,
G. W. McKnight, and D. E. MacIntyre.
1992.
Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence.
Inflammation
16:343-354[Medline].
|
| 36.
|
Whitington, P. F.,
A. L. Friedman, and R. W. Chesney.
1979.
Gastrointestinal disease in the hemolytic uremic syndrome.
Gastroenterology
76:728-733[Medline].
|
| 37.
|
Yamasaki, C.,
Y. Natori,
X.-T. Zeng,
M. Ohmura,
S. Yamasaki,
Y. Takeda, and Y. Natori.
1999.
Induction of cytokines in a human colon epithelial cell line by Shiga toxin 1 (Stx1) and Stx2 but not by non-toxic mutant Stx1 which lacks N-glycosidase activity.
FEBS Lett.
442:231-234[Medline].
|
| 38.
|
Zinck, R.,
M. A. Cahill,
M. Kracht,
C. Sachsenmaier,
R. A. Hipskind, and A. Nordheim.
1995.
Protein synthesis inhibitors reveal differential regulation of mitogen-activated protein kinase and stress-activated protein kinase pathways that converge on Elk-1.
Mol. Cell. Biol.
15:4930-4938[Abstract].
|
Infection and Immunity, November 1999, p. 5985-5993, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gray, J. S., Bae, H. K., Li, J. C. B., Lau, A. S., Pestka, J. J.
(2008). Double-Stranded RNA-Activated Protein Kinase Mediates Induction of Interleukin-8 Expression by Deoxynivalenol, Shiga Toxin 1, and Ricin in Monocytes. Toxicol Sci
105: 322-330
[Abstract]
[Full Text]
-
Zanchi, C., Zoja, C., Morigi, M., Valsecchi, F., Liu, X. Y., Rottoli, D., Locatelli, M., Buelli, S., Pezzotta, A., Mapelli, P., Geelen, J., Remuzzi, G., Hawiger, J.
(2008). Fractalkine and CX3CR1 Mediate Leukocyte Capture by Endothelium in Response to Shiga Toxin. J. Immunol.
181: 1460-1469
[Abstract]
[Full Text]
-
Stone, M. K., Kolling, G. L., Lindner, M. H., Obrig, T. G.
(2008). p38 Mitogen-Activated Protein Kinase Mediates Lipopolysaccharide and Tumor Necrosis Factor Alpha Induction of Shiga Toxin 2 Sensitivity in Human Umbilical Vein Endothelial Cells. Infect. Immun.
76: 1115-1121
[Abstract]
[Full Text]
-
Gobert, A. P., Vareille, M., Glasser, A.-L., Hindre, T., de Sablet, T., Martin, C.
(2007). Shiga Toxin Produced by Enterohemorrhagic Escherichia coli Inhibits PI3K/NF-{kappa}B Signaling Pathway in Globotriaosylceramide-3-Negative Human Intestinal Epithelial Cells. J. Immunol.
178: 8168-8174
[Abstract]
[Full Text]
-
Yoder, J. M., Aslam, R. U., Mantis, N. J.
(2007). Evidence for Widespread Epithelial Damage and Coincident Production of Monocyte Chemotactic Protein 1 in a Murine Model of Intestinal Ricin Intoxication. Infect. Immun.
75: 1745-1750
[Abstract]
[Full Text]
-
Lee, S.-Y., Cherla, R. P., Tesh, V. L.
(2007). Simultaneous Induction of Apoptotic and Survival Signaling Pathways in Macrophage-Like THP-1 Cells by Shiga Toxin 1. Infect. Immun.
75: 1291-1302
[Abstract]
[Full Text]
-
Torres, A. G., Li, Y., Tutt, C. B., Xin, L., Eaves-Pyles, T., Soong, L.
(2006). Outer Membrane Protein A of Escherichia coli O157:H7 Stimulates Dendritic Cell Activation.. Infect. Immun.
74: 2676-2685
[Abstract]
[Full Text]
-
Rogers, T. J., Paton, J. C., Wang, H., Talbot, U. M., Paton, A. W.
(2006). Reduced Virulence of an fliC Mutant of Shiga-Toxigenic Escherichia coli O113:H21. Infect. Immun.
74: 1962-1966
[Abstract]
[Full Text]
-
Cherla, R. P., Lee, S.-Y., Mees, P. L., Tesh, V. L.
(2006). Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line. J. Leukoc. Biol.
79: 397-407
[Abstract]
[Full Text]
-
Nolasco, L. H., Turner, N. A., Bernardo, A., Tao, Z., Cleary, T. G., Dong, J.-f., Moake, J. L.
(2005). Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood
106: 4199-4209
[Abstract]
[Full Text]
-
Harrison, L. M., van den Hoogen, C., van Haaften, W. C. E., Tesh, V. L.
(2005). Chemokine Expression in the Monocytic Cell Line THP-1 in Response to Purified Shiga Toxin 1 and/or Lipopolysaccharides. Infect. Immun.
73: 403-412
[Abstract]
[Full Text]
-
Korcheva, V., Wong, J., Corless, C., Iordanov, M., Magun, B.
(2005). Administration of Ricin Induces a Severe Inflammatory Response via Nonredundant Stimulation of ERK, JNK, and P38 MAPK and Provides a Mouse Model of Hemolytic Uremic Syndrome. Am. J. Pathol.
166: 323-339
[Abstract]
[Full Text]
-
Wu, S., Powell, J., Mathioudakis, N., Kane, S., Fernandez, E., Sears, C. L.
(2004). Bacteroides fragilis Enterotoxin Induces Intestinal Epithelial Cell Secretion of Interleukin-8 through Mitogen-Activated Protein Kinases and a Tyrosine Kinase-Regulated Nuclear Factor-{kappa}B Pathway. Infect. Immun.
72: 5832-5839
[Abstract]
[Full Text]
-
Ritchie, J. M., Thorpe, C. M., Rogers, A. B., Waldor, M. K.
(2003). Critical Roles for stx2, eae, and tir in Enterohemorrhagic Escherichia coli-Induced Diarrhea and Intestinal Inflammation in Infant Rabbits. Infect. Immun.
71: 7129-7139
[Abstract]
[Full Text]
-
Higuchi, S., Tamura, T., Oda, T.
(2003). Cross-Talk between the Pathways Leading to the Induction of Apoptosis and the Secretion of Tumor Necrosis Factor-{alpha} in Ricin-Treated RAW 264.7 Cells. J Biochem
134: 927-933
[Abstract]
[Full Text]
-
Rogers, T. J., Paton, A. W., McColl, S. R., Paton, J. C.
(2003). Enhanced CXC Chemokine Responses of Human Colonic Epithelial Cells to Locus of Enterocyte Effacement-Negative Shiga-Toxigenic Escherichia coli. Infect. Immun.
71: 5623-5632
[Abstract]
[Full Text]
-
Matussek, A., Lauber, J., Bergau, A., Hansen, W., Rohde, M., Dittmar, K. E. J., Gunzer, M., Mengel, M., Gatzlaff, P., Hartmann, M., Buer, J., Gunzer, F.
(2003). Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood
102: 1323-1332
[Abstract]
[Full Text]
-
Zhou, X., Giron, J. A., Torres, A. G., Crawford, J. A., Negrete, E., Vogel, S. N., Kaper, J. B.
(2003). Flagellin of Enteropathogenic Escherichia coli Stimulates Interleukin-8 Production in T84 Cells. Infect. Immun.
71: 2120-2129
[Abstract]
[Full Text]
-
Brett, K. N., Ramachandran, V., Hornitzky, M. A., Bettelheim, K. A., Walker, M. J., Djordjevic, S. P.
(2003). stx1c Is the Most Common Shiga Toxin 1 Subtype among Shiga Toxin-Producing Escherichia coli Isolates from Sheep but Not among Isolates from Cattle. J. Clin. Microbiol.
41: 926-936
[Abstract]
[Full Text]
-
Smith, W. E., Kane, A. V., Campbell, S. T., Acheson, D. W. K., Cochran, B. H., Thorpe, C. M.
(2003). Shiga Toxin 1 Triggers a Ribotoxic Stress Response Leading to p38 and JNK Activation and Induction of Apoptosis in Intestinal Epithelial Cells. Infect. Immun.
71: 1497-1504
[Abstract]
[Full Text]
-
Imai, Y., Fukui, T., Kurohane, K., Miyamoto, D., Suzuki, Y., Ishikawa, T., Ono, Y., Miyake, M.
(2003). Restricted Expression of Shiga Toxin Binding Sites on Mucosal Epithelium of Mouse Distal Colon. Infect. Immun.
71: 985-990
[Abstract]
[Full Text]
-
Moake, J. L.
(2002). Thrombotic Microangiopathies. NEJM
347: 589-600
[Full Text]
-
Dahan, S., Busuttil, V., Imbert, V., Peyron, J.-F., Rampal, P., Czerucka, D.
(2002). Enterohemorrhagic Escherichia coli Infection Induces Interleukin-8 Production via Activation of Mitogen-Activated Protein Kinases and the Transcription Factors NF-{kappa}B and AP-1 in T84 Cells. Infect. Immun.
70: 2304-2310
[Abstract]
[Full Text]
-
Ray, P., Acheson, D., Chitrakar, R., Cnaan, A., Gibbs, K., Hirschman, G. H., Christen, E., Trachtman, H.
(2002). Basic Fibroblast Growth Factor among Children with Diarrhea-Associated Hemolytic Uremic Syndrome. J. Am. Soc. Nephrol.
13: 699-707
[Abstract]
[Full Text]
-
Stevens, M. P., Marches, O., Campbell, J., Huter, V., Frankel, G., Phillips, A. D., Oswald, E., Wallis, T. S.
(2002). Intimin, Tir, and Shiga Toxin 1 Do Not Influence Enteropathogenic Responses to Shiga Toxin-Producing Escherichia coli in Bovine Ligated Intestinal Loops. Infect. Immun.
70: 945-952
[Abstract]
[Full Text]
-
HOEY, D.E. E., CURRIE, C., ELSE, R. W., NUTIKKA, A., LINGWOOD, C. A., GALLY, D. L., SMITH, D. G. E.
(2002). Expression of receptors for verotoxin 1 from Escherichia coli O157 on bovine intestinal epithelium. J Med Microbiol
51: 143-149
[Abstract]
[Full Text]
-
Foster, G. H., Tesh, V. L.
(2002). Shiga toxin 1-induced activation of c-Jun NH2-terminal kinase and p38 in the human monocytic cell line THP-1: possible involvement in the production of TNF-{alpha}. J. Leukoc. Biol.
71: 107-114
[Abstract]
[Full Text]
-
Thorpe, C. M., Smith, W. E., Hurley, B. P., Acheson, D. W. K.
(2001). Shiga Toxins Induce, Superinduce, and Stabilize a Variety of C-X-C Chemokine mRNAs in Intestinal Epithelial Cells, Resulting in Increased Chemokine Expression. Infect. Immun.
69: 6140-6147
[Abstract]
[Full Text]
-
Hurley, B. P., Thorpe, C. M., Acheson, D. W. K.
(2001). Shiga Toxin Translocation across Intestinal Epithelial Cells Is Enhanced by Neutrophil Transmigration. Infect. Immun.
69: 6148-6155
[Abstract]
[Full Text]
-
Akkoyunlu, M., Malawista, S. E., Anguita, J., Fikrig, E.
(2001). Exploitation of Interleukin-8-Induced Neutrophil Chemotaxis by the Agent of Human Granulocytic Ehrlichiosis. Infect. Immun.
69: 5577-5588
[Abstract]
[Full Text]
-
Karpman, D., Papadopoulou, D., Nilsson, K., Sjogren, A.-C., Mikaelsson, C., Lethagen, S.
(2001). Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood
97: 3100-3108
[Abstract]
[Full Text]
-
Izadpanah, A., Dwinell, M. B., Eckmann, L., Varki, N. M., Kagnoff, M. F.
(2001). Regulated MIP-3{alpha}/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. Am. J. Physiol. Gastrointest. Liver Physiol.
280: G710-G719
[Abstract]
[Full Text]
-
Foster, G. H., Armstrong, C. S., Sakiri, R., Tesh, V. L.
(2000). Shiga Toxin-Induced Tumor Necrosis Factor Alpha Expression: Requirement for Toxin Enzymatic Activity and Monocyte Protein Kinase C and Protein Tyrosine Kinases. Infect. Immun.
68: 5183-5189
[Abstract]
[Full Text]